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KEMAJUAN PENELZTIAN MENGENAZ PEMAKIT DZARE 
OLEH NAMRU-2, BADAN LZTBANGKES DAN R W  
Penyakit diare termasuk kolera masih merupakan masalah kesehatan yang penting untuk 
Indonesia. Kejadian luar biasa ('KLB) "muntah-berak" masih terus dilaporkan dari berbagai daerah 
di Indonesia. Salah satu upaya yang dilakukan unruk n~engatasi keadaan ini adalah tnenemukan suatu 
vaksin yang aman, praktis dun terjangkau harganya. CVD-103 adalah strain I/. cholerae yang 
sebagian besar gen penyebab diare, toksin subunit A, telah dibuang. 
Pada penelitian dengan peserta anak-anak di Jakarta, CVD 103-HgR ternyata metnberikan 
kenaikan antibodi dun dapat diterima baik oleh anak-anak Indonesia berusia 5-9 tahun dun 25-59 
bulan. Di samping itu pemeriksaan satnpel bakteriologik dari lingkungan dekat tempat kediatnan 
peserta dengan menggunakan teknik yang peka untuk mendetehi C/: cholerae, tidak menemukan 
adanya strain vaksin. 
Suatu penelitian lapangan dengan tujuan untuk menilai kemanjuran dosis tunggal vaksin oral 
kolera CVD 103-HgR untuk pencegahan koleru secara klinis selama tiga tahun, telah dimulai 
didaerah Jakarta Utara pada tahun 1993. Selain itu penelitian in; juga bertujuan untuk menetapkan 
kemanjuran vaksin terhadap berbagai kelompok uniur, terhadap kolera berat, serta metnbandingkan 
kemanjurannya pada peserta dengan golongan darah 0 .  Jumlah penduduk yang ikut dalam penilaian 
vaksin in; adalah 67.000peserta sukarela. Hasil penelitian in; diharapkan dapat diketahui pada akhir 
tahun 1996. 
Di samping penelitian tentang vabin kolera, NAMRU dan Badan Litbangkes juga telah ikut 
serta dalam berbagai penelitian WHO, misalnya fentang larufan garatn oralif (ORS) yang dilakukan 
di RS Karantina/RS Penyakit Infeksi ProJ Dr. Sulianti Saroso. Salah safu penelifian terakhir adalah 
manfaat larutan ORS dengan osmolaritas rendah pada tahun 1994. tiasil penelitian ini te/ah 
mendorong WHO untuk melaksanakan penelitian dengan larutan yang sarna rli berbagai pusat 
penelitian (multicenter) pada tahun 1995 sebelum tnengusulkan suatu peruhahan fornzulasr larutan 
ORS secara global. 
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INTRODUCTION 
Diarrheal diseases including cholera 
continue to be an important cause of 
dehydration and death among residents of 
Indonesia. Cholera occurs in endemic form in 
rural areas and cities, including Jakarta, and 
occurs sporadically in epidemic form. The 
history of the seventh pandemic begins with the 
detection of the El Tor biotype of Vihrio 
cholerae 01 in south Sulawesi in 1961. From 
Indonesia. this strain spread throughout the 
developing world over the next 30 years. This 
included a major outbreak of cholera in 199 1 in 
South America, involving over 550,000 
individuals with thousands of deaths'. 
During 1994 and 1995, outbreaks of 
cholera have been documented in many areas of 
Indonesia, including Ciamis, Bekasi, and Garut 
in Java, Pulau Panggang (Kepulauan Seribu), 
Biak, Bali, Palembang, Pontianak, and West 
Timor. CDC continue to maintain active 
surveillance for cholera in outbreak situations, 
however, NAMRU-2 and NIHRD were involved 
frequently. In addition, the introduction of the 
0139 strain of V.  cholerae is being monitored in 
several sites in Indonesia, through the 
collaboration of NAMRU with local hospitals in 
various cities and Badan Litbangkes. 
Cholera pathogenesis begins with 
attachment of the cholera bacteria to the small 
intestinal mucosa. Mucosal cells are then 
stimulated by the A subunit of the cholera toxin 
to secrete sodium into the intestinal lumen; 
water and potassium follow. V. cholerae 01 
may cause asymptomatic colonization of the 
intestine, mild diarrhea, or the severe form with 
massive fluid loss and dehydration. Death can 
result if fluid replacement via the oral or 
intravenous route is not instituted promptly. 
Prevention of cholera involves provision of 
clean water, proper sewage disposal, and 
avoidance of food contamination, but these 
measures are difficult to implement in many 
developing areas with scarce resources. Cholera 
illness provides immunological protection to 
those who survive the diarrhea, but it is often of 
short duration. Because of the presumption that 
natural immunity occurs in populations in 
whom cholera disease is endemic, vaccine 
development has been pursued. 
The parenteral inactivated whole cell 
cholera vaccine has largely been abandoned as a 
public health tool for the control of cholera, due 
o low efficacy for only about 6 months2. The 
oral killed vaccine (inactivated V. cholerae 01) 
with or without the non-toxic B subunit of 
cholera toxin, displayed some efficacy in trial in 
Bangladesh in the 1980s'. This vaccine 
requires a 3dose immunization schedule. 
Demonstrated efficacy of about 50% was an 
improvement over the previous vaccines, but 
because of low efficacy in children under age 6, 
and the need for 3 doses, other vaccines have 
been under development4. In addition, the oral 
inactivated vaccine provided lower protection to 
individuals of blood group 0 ,  who are at greater 
risk than others for severe diseasek6. 
It is the hope of the World Health 
Organization that a vaccine can be found which 
provides protection against cholera with a high 
eflicacy rate after a single dose in a susceptible 
population, especially young children and 
persons with blood group 0. If affordable, such 
a cholera vaccine could be usehl in the control 
of endemic and possib!y epidemic cholera. 
ORAL CVDlO3-HgR VACCINE TRIAL 
The University of Maryland Center for 
Vaccine Development produced the oral vaccine 
CVD103-HgR by genetic engineering, as a 
possible candidate for the prevention of cholera. 
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This is a live vaccine which is derived from a 
virulent strain by deletion of most of the genes 
for the toxic A subunit of cholera toxin, while 
the B subunit which stimulates the immune 
response is preserved. A mercury resistance 
gene was inserted to enable researchers to 
distinguish the vaccine strain from wild C.: 
cholerae 0 1 .' 
Challenge studies in North American 
volunteers showed protection from severe or 
moderate diarrhea by one oral dose of 
CVD103-HgR when challenged with V. 
cholerae 01. '3 9. lo. The protection lasted for at 
least six months, and began eight days after 
taking the vaccinelo. 
Studies among volunteers in developed 
and developing countries demonstrated that the 
CVD 103-HgR strain is safe, with no more 
adverse reactions than placebo. These studies 
also demonstrated the immunogenicity of one 
oral dose of CVD 103-HgR, as measured by 
high serum vibriocidal antibody responses, 
which correlate with protection "-". 
Trials of the CVD 103-HgR vaccine in 
Jakarta investigated the reactogenicity, 
immunogenicity and transmissibility of CVD 
103-HgR when given to children ages 2-4 years 
and 5-9 years. The vaccine was found to be 
highly immunogenic and well-tolerated in these 
Indonesian children. In only < 0.5% of 
vaccinees was the vaccine strain recovered 
from stool cultures, and only minimal evidence 
of transmissibility to family members was 
found '4.'5. 
Data from prospective surveillance for 
cholera at the Infectious Disease Hospital 
(formerly the Rumah Sakit Karantina, now 
named Rumah Sakit Penyakit Infeksi Professor 
Sulianti Saroso) during 1992-93, revealed that 
cholera continues to be endemic in North 
Jakarta, with incidences sufficiently high to 
just@ an efficacy trial of the CVD 103-HgR 
vaccine in this area. 
In collaboration with the Indonesian 
Ministry of Health, the Indonesian CDC and 
Litbangkes, and with the advice and support of 
the WHO, the Swiss Serum and Vaccine 
Institute, and the University of Maryland Center 
for Vaccine Development, a large-scale efficacy 
trial of the vaccine was initiated in April, 1993. 
The objectives of the trial are: 
1. To assess the effectiveness of one dose of 
the oral cholera vaccine CVD 103-HgR in 
preventing cholera of a severity that leads 
the patient to seek medical care at a 
hospital or clinic, over a period of three 
years. 
2. To determine vaccine efficacy according to 
age, severity of illness, and/or blood group. 
The study is currently in progress, with 
over one year of surveillance for cholera illness 
completed among the over 67,000 vaccine 
participants. Eficacy data will be available 
after completion of the 3 years of surveillance. 
Included in the study is long-term safety 
monitoring at the hospital and community level, 
assessment of vaccine immunogenicity, and 
evaluation of side effects. Close cooperation 
with hospital staff, comniunity leaders, and 
vaccination participants is maintained. and has 
been accompanied by excellent assistance at all 
levels. 
The institutions collaborating in t h ~ s  tudy 
include the National Institute of Health 
Research and Development (Badan Penelitian 
dan Pengembangan Kesehatan Indonesia. 
Litbangkes), the Naval Medical Research 
Unit-Two (NAMRU-2). the Directorate General 
of CDC, Ministry of Hcalth Republic of 
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Indonesia (Direktorat Jenderal P2M&PLP 
Depkes RI), and the University of Indonesia. 
The hospitals are critical to the success of the 
project, specifically the Rumah Sakit Penyakit 
Infeksi Prof. Sulianti Saroso (RSPI-SS), Rumah 
Sakit Atmajaya, Rumah Sakit Koja, and Rumah 
Sakit Islam in Sukapura, all North Jakarta 
hospitals. International organization which are 
supporting and advising the study are the World 
Health Organization, the Swiss Serum and 
Vaccine Institute, and the University of 
Maryland. 
O T H E R  STUDIES ON DIARRHOEAL 
DISEASES 
In addition to this vaccine trial. NAMRU 
and Litbangkes have been involved in studies 
evaluating the efficacies of various oral 
rehydration solutions, in the pursuit of 
improved ORS to treat dehydration and 
diarrhea. These studies have been conducted at 
the Rumah Sakit Penyakit Infeksi Prof. Dr. 
Sulianti Saroso. The latest trial of this kind was 
the evaluation of a solution with a lower 
osmolarity than standard ORS, by a reduced 
amount of sugar and sodium content. This 
solution appears to be an improvement in the 
rehydration of children and for rehydration 
when non-cholera illness is seen. This study, 
was conducted in 1994 in Jakarta and in Dhaka. 
Supported by encouraging data from the trials, 
the WHO is sponsoring multicenter trials to 
confirm the results and assess whether a change 
in the recommended composition of ORS 
s t A ~ u l d  bc adopted. 
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